Please use this identifier to cite or link to this item:
|Title:||Choice of time period to identify confounders for propensity score matching, affected the estimate: a retrospective cohort study of drug effectiveness in asthmatic children||Authors:||Osokogu, Osemeke U.
de Ridder, Maria
Sturkenboom, Miriam C. J. M.
|Issue Date:||2018||Publisher:||ELSEVIER SCIENCE INC||Source:||JOURNAL OF CLINICAL EPIDEMIOLOGY, 101, p. 107-115||Abstract:||Objectives: To control for confounding by indication in comparative (drug) effectiveness studies, propensity score (PS) methods may be used. Since childhood diseases or outcomes often present as acute events, we compared the effect of using different look-back periods in electronic health-care data, to construct PSs. This was applied in our research on the effect of a combination of inhaled corticosteroids/long-acting beta-2 agonists (ICS + LABA), either as fixed combination or used as loose combination (2 separate inhaler devices) in the prevention of severe asthma exacerbations. Methods: We created a cohort of children (5-17 years) diagnosed with asthma from the Dutch Integrated Primary Care information database. Within this cohort, we identified new users of ICS + LABA, either as fixed combination or loose combination (2 separate inhaler devices). The outcome of interest was severe asthma exacerbations. PSs for type of treatment were created using comorbidity and drug use history in different time windows: 1 week, 1 month, 3 months, 1 year, and full history prior to the start of treatment. PSs were used for matching subjects in both exposure groups. Time to first asthma exacerbation was analyzed with Cox proportional hazard regression. The results were compared with published clinical trials. Results: Of 39,682 asthmatic children, 3,500 (8.8%) were new users of either ICS + LABA fixed (3,324 [95.0%]) or loose (176 [5.0%]). The crude hazard ratio (HR) for a severe asthma exacerbation, comparing ICS + LABA fixed to loose was 0.37 (95% confidence interval [CI]: 0.20-0.66). PS-matched HRs (1 week, 1 month, 3 month, 1 year, and full history) were 0.48 (95% CI: 0.22-1.04); 0.60 (95% CI: 0.26-1.38), 0.69 (95% CI: 0.31-1.57), 0.56 (CI: 0.25-1.24), and 0.58 (CI: 0.24-1.36), respectively. Conclusions: PS matching can be used to control for confounding in pediatric comparative (drug) effectiveness studies, the impact of different look-back periods to implement the PS is important. Controlling for confounders occurring in the 3 months preceding drug exposure may yield results comparable to clinical trial results. (C) 2018 Elsevier Inc. All rights reserved.||Notes:||[Osokogu, Osemeke U.; Khan, Javeed; Nakato, Swabra; Weibel, Daniel; de Ridder, Maria; Sturkenboom, Miriam C. J. M.; Verhamme, Katia] Erasmus Univ, Med Ctr, Dept Med Informat, NL-3015 GE Rotterdam, Netherlands. [Khan, Javeed] Univ Hasselt, Dept Stat, BE-3590 Diepenbeek, Belgium. [Verhamme, Katia] Univ Ghent, Fac Pharmaceut Sci, Dept Bioanal, Ghent, Belgium.||Keywords:||Propensity scores; Comparative effectiveness; Pediatrics;Propensity scores; Comparative effectiveness; Pediatrics||Document URI:||http://hdl.handle.net/1942/28812||ISSN:||0895-4356||e-ISSN:||1878-5921||DOI:||10.1016/j.jclinepi.2018.01.008||ISI #:||000443520000013||Rights:||2018 Elsevier Inc. All rights reserved.||Category:||A1||Type:||Journal Contribution||Validations:||ecoom 2019|
|Appears in Collections:||Research publications|
Show full item record
Files in This Item:
|Published version||302.4 kB||Adobe PDF||View/Open Request a copy|
checked on Sep 2, 2020
WEB OF SCIENCETM
checked on May 21, 2022
checked on May 19, 2022
checked on May 19, 2022
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.